D-dimer Testing Market Expected to Show a Significant Growth During the Forecast Period 2022 – 2027

Posted on 2022-06-07 by researchinsights in Healthcare // 0 Comments

San Francisco, California , USA, June 07, 2022 — /EPR Network/ —

D-dimer Testing Industry Overview

The global D-dimer testing market size was valued at USD 1.2 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 4.3% from 2020 to 2027.

A paradigm shift towards the demand for next-generation point-of-care D-dimer testing has driven the market. This is because the implementation of POC solutions significantly reduces waiting time, minimizes the length of patient stay, enables faster diagnosis, and results in improved patient experience. The resounding benefits gained from these solutions in POC settings are considered to boost the growth of the market for D-dimer testing. A rise in the incidence rate of Venous Thromboembolism (VTE) coupled with various pulmonary and cardiovascular diseases that cause life-threatening issues due to blood clot formation is increasing the demand for D-dimer testing.

Gather more insights about the market drivers, restrains and growth of the Global D-dimer Testing market

As per estimates of the Centers for Disease Control and Prevention (CDC), around 900,000 people are affected with VTE each year and nearly 60,000-100,000 Americans die due to VTE in the U.S. The advent of aptamers that can reduce the use of antibodies for D-dimer testing is proven to be a cost-effective and long-lasting approach in D-dimer testing. Aptamers are also affordable, stable, and faster to produce as well as possess a longer shelf life as compared to antibodies, thus creating lucrative opportunities for market growth. For instance, aptamers provided by Ayass Bioscience, LLC are observed to be useful in homogeneous assays and manual POC agglutination tests.

Extensive research studies have predicted that elevated D-dimer levels serve as a valuable marker in several clinical conditions, such as atrial fibrillation, HIV infection, coronary artery disease, and acute pancreatitis. For instance, systemic alterations in coagulation are related to complications of acute pancreatitis. Hence, D-dimer levels can be used in the risk assessment of acute pancreatitis. Such research findings are anticipated to broaden the application scope of these tests.

The effects of heterophilic antibodies on the estimation of the D-dimer level remain a big challenge in the clinical examination of cardiac and other diseases. This results in significant differences in the end results. Studies suggest that the combination of instrumental methods, incorporation of heterophilic antibody blockers along with clinical performance and imaging data can rule out this interference, thus pronouncing the need for further research in this sector.

Browse through Grand View Research’s Clinical Diagnostics Industry Research Reports.

Primary Care POC Diagnostics Market – The global primary care POC diagnostics market size was estimated at USD 6.3 billion in 2016. The rapid evolution of point-of-care testing (POCT) holds enormous potential for the growth of both primary and secondary care settings.
Blood Screening Market – The global blood screening market size was valued at USD 1.6 billion in 2015 and is projected to grow at a CAGR of 10.2% over the forecast period. Blood screening is a process in which donated blood is screened for various infectious diseases such as HBV, HCV, HIV1, and HIV2.

D-dimer Testing Market Segmentation

Grand View Research has segmented the global D-dimer testing market based on product, test type, method, application, end-use, and region:

D-dimer Testing Product Outlook (Revenue, USD Million, 2016 – 2027)
- Analyzers
- Reagents & Consumables
D-dimer Testing Test Type Outlook (Revenue, USD Million, 2016 – 2027)
- Clinical Laboratory Tests
- Point-of-Care Tests
D-dimer Testing Method Outlook (Revenue, USD Million, 2016 – 2027)
- Enzyme-linked Immunosorbent Assay (ELISA)
- Latex-enhanced Immunoturbidimetric Assays
- Fluorescence Immunoassays
- Others
D-dimer Testing Application Outlook (Revenue, USD Million, 2016 – 2027)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Disseminated Intravascular Coagulation (DIC)
- Others
D-dimer Testing End-use Outlook (Revenue, USD Million, 2016 – 2027)
- Hospitals
- Academic & Research Institutes
- Diagnostic Centers
- Others
D-dimer Testing Regional Outlook (Revenue, USD Million, 2016 – 2027)
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)

Market Share Insights

April 2019: Ortho Clinical Diagnostics, a U.S.-based company, launched its D-Dimer assay in collaboration with Diazyme Laboratories, Inc. This new assay is one of the latest product of MicroTip Partnership Assay Program of Ortho Clinical, which allow the company to provide high value, flexible, quick, and esoteric testing solutions.

Key Companies profiled:

Some prominent players in the global D-dimer testing market include

Thermo Fisher Scientific Inc.
Hoffmann-La Roche Ltd.
Siemen Healthineers
Abbott
biomérieux SA
WERFEN
HORIBA, Ltd.
Quidel Corporation
Diazyme Laboratories, Inc.
Biomedica Diagnostics
Sekisui Diagnostics

Order a free sample PDF of the D-dimer Testing Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Matched content

Editor’s pick